Lv7
3350 积分 2020-09-07 加入
Pilot Study of “Less is More” Rezum for Treatment of BPH
9小时前
待确认
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial
11小时前
待确认
Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes
14天前
已完结
Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study
1个月前
已完结
Spatially resolved transcriptomic analysis of the adult human prostate
1个月前
已完结
Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial
1个月前
已完结
KMT2C deficiency drives transdifferentiation of double-negative prostate cancer and confer resistance to AR-targeted therapy
1个月前
已完结
Prostate cancer
2个月前
已完结
Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity
3个月前
已完结
KMT2C deficiency drives transdifferentiation of double-negative prostate cancer and confer resistance to AR-targeted therapy
3个月前
已完结
皖公网安备34019202002308
